Deadly Diseases That Can Actually Be Cured

Several diseases that were historically death sentences now have outright cures, not just lifelong treatments that slow progression. Hepatitis C, once a leading cause of liver failure worldwide, is eliminated in over 95% of patients with a short course of pills. Certain aggressive cancers, fatal parasitic infections, and even genetic conditions once considered permanently embedded in a person’s DNA have crossed from “terminal” to “fixable.” The list is longer and more surprising than most people realize, though the gap between a cure existing and a cure reaching the people who need it remains a persistent problem.

Hepatitis C

For decades, hepatitis C was a slow-burning crisis. The virus quietly destroyed the liver over years, often going undetected until cirrhosis or liver cancer had already set in. Interferon-based treatments were grueling, lasted nearly a year, and failed in a large share of patients. Then, starting around 2014, a new class of drugs called direct-acting antivirals changed everything. These pills target the virus’s own replication machinery, and they work fast. A typical course runs eight to twelve weeks, and cure rates now exceed 95% across all major viral genotypes.¹

Those numbers hold up in real-world settings outside wealthy countries. A cohort study in Vietnam found sustained virological response rates of roughly 98 to 100% across genotypes 1, 2, 6, and mixed genotypes.² A demonstration project in Cameroon, where patients had a range of liver disease stages and genotypes, achieved a cure rate above 96% among people who completed treatment.³ “Cure” here means the virus is undetectable in the blood twelve weeks after finishing pills, a standard called sustained virological response. It is a genuine cure. The virus does not come back. The remaining challenge is finding and treating the millions of people worldwide who still carry hepatitis C without knowing it.

Cancers That Went from Fatal to Curable

Cancer is not one disease, and the word “cure” still does not apply to most forms of it. But a few cancers that were once near-universally fatal are now cured routinely, sometimes with surprisingly simple regimens.

Acute promyelocytic leukemia, or APL, is the standout. This subtype of blood cancer was one of the deadliest leukemias just a few decades ago. Patients could die within days of diagnosis from catastrophic bleeding. Today, a combination of two drugs, all-trans retinoic acid and arsenic trioxide, pushes complete remission rates to 100% in evaluable patients and two-year event-free survival above 97%.⁴ The treatment works by degrading the abnormal protein that drives the cancer, essentially forcing the leukemic cells to mature and self-destruct.⁵ APL is now considered one of the most curable cancers in adults, but only if it is recognized quickly enough. Misdiagnosis or delayed treatment still kills people, because the early bleeding complications can be fatal before the drugs have time to work.

Testicular cancer tells a similar story of transformation. Before the mid-1970s, metastatic testicular cancer had a cure rate of around 5%. The introduction of cisplatin-based chemotherapy changed that to about 60%, and subsequent refinements pushed it higher still. The standard regimen today, bleomycin plus etoposide plus cisplatin, has been the backbone of treatment since the 1980s and produces less toxicity and better outcomes than earlier combinations.⁶ Part of the reason testicular cancer responds so well is that the tumor cells have inherently poor DNA repair and are unusually sensitive to the DNA damage that cisplatin causes.⁷ Even patients who relapse after first-line treatment can often be cured with salvage chemotherapy, something almost unheard of in other solid tumors.

Choriocarcinoma, a rare and aggressive cancer that arises from placental tissue, follows a similar pattern. Despite being fast-growing and capable of spreading widely, it is exquisitely sensitive to chemotherapy. First-line combination regimens achieve complete remission in roughly 80 to 88% of high-risk patients.⁸

Perhaps the most counterintuitive cancer cure involves antibiotics. A type of stomach lymphoma called MALT lymphoma is driven by chronic infection with the bacterium Helicobacter pylori. In localized cases, simply eradicating the bacterium with a standard course of antibiotics causes the cancer to regress. A long-term study of 105 patients found that about three quarters achieved histological regression of their lymphoma after H. pylori eradication alone, with the majority reaching complete remission.⁹ No chemotherapy, no radiation. Just antibiotics killing the infection that was fueling the cancer.

Rabies and the Narrow Window

Rabies occupies a strange category: a disease that is essentially 100% fatal once symptoms appear, yet nearly 100% preventable if treated beforehand. The key is post-exposure prophylaxis, a series of vaccine doses given after a bite from a potentially rabid animal. When administered before the virus reaches the brain, PEP works with extraordinary reliability. A systematic review of prophylactic vaccination regimens found that all comparison groups eventually achieved protective antibody levels, regardless of whether the standard five-dose or accelerated four-dose schedule was used.¹⁰ Even in specific populations like obese patients, where immune responses can sometimes be blunted, seroconversion reached 100% by day 14.¹¹

The treatment is also evolving. For severe exposures, immunoglobulin is injected directly into the wound alongside the vaccine to provide immediate neutralizing antibodies while the vaccine takes effect. Newer monoclonal antibody products are being developed that achieve higher and faster antibody levels than traditional immunoglobulin, with one recent study showing over 99.8% seroconversion by day three.¹² The catch, of course, is access. Rabies kills tens of thousands of people every year, mostly in parts of Africa and Asia where post-exposure treatment is unavailable or unaffordable. The cure exists; the distribution system does not.

African Sleeping Sickness

Human African trypanosomiasis, commonly called sleeping sickness, is caused by parasites transmitted through the bite of tsetse flies. Left untreated, it invades the central nervous system, causes severe neurological decline, and is uniformly fatal. For most of the disease’s history, treatment required toxic intravenous drugs administered in a hospital, some of which were themselves dangerous. The drug melarsoprol, an arsenic-based compound, killed a significant percentage of the patients it was meant to save.

Fexinidazole changed this. It is an oral drug that can be taken at home, effective against both the early and late stages of the disease. Preclinical studies showed it cured both acute and chronic infections in animal models, and it works against both main forms of the parasite that infect humans.¹³ Its approval marked the first all-oral treatment for sleeping sickness and represented a genuine shift in what it means to manage a neglected tropical disease. An oral pill that a patient can swallow at home is a fundamentally different proposition from intravenous arsenic in a hospital.

Gene Therapy for Genetic Diseases

Until recently, diseases caused by defective genes were by definition incurable. You could treat symptoms, but you could not fix the underlying code. Gene therapy has started to change that for a small but growing number of conditions.

Spinal muscular atrophy type 1 is the most dramatic example. SMA1 is the leading genetic cause of infant death. Without treatment, babies lose the ability to move, swallow, and breathe, with most dying before their second birthday. Onasemnogene abeparvovec, sold as Zolgensma, delivers a working copy of the missing gene through a single intravenous infusion. In pooled clinical data, infants treated with the gene therapy showed rapid motor function gains, with an average improvement of nearly 12 points on a standard motor scale within three months.¹⁴ In one study, 11 of 15 treated infants could sit unassisted, 11 could speak, and two walked independently, milestones that are unheard of in untreated SMA1.¹⁵ The therapy is not perfect; it carries risks including liver toxicity, and outcomes depend heavily on how early treatment begins. But for a disease that used to guarantee death in infancy, having children sit, eat, and talk is a seismic shift.

Sickle cell disease, which affects millions of people worldwide and causes chronic pain, organ damage, and shortened lifespan, is another target of gene editing. CRISPR-based therapies work by disabling a gene called BCL11A, which normally suppresses fetal hemoglobin production. With that gene turned off, red blood cells produce higher levels of fetal hemoglobin, which prevents the sickling that causes the disease’s damage.¹⁶ The first CRISPR-based therapy for sickle cell disease received regulatory approval in late 2023, marking one of the earliest approved uses of gene editing as medicine.

Severe combined immunodeficiency, sometimes called “bubble boy disease” because affected children have virtually no functional immune system, was among the first targets of gene therapy decades ago. Early trials were marred by cases of treatment-related leukemia. But updated approaches have shown that the correction holds. After nearly a decade of follow-up, gene therapy was shown to have corrected the immune deficiency in children with the X-linked form of SCID, offering an alternative for patients without a matched bone marrow donor.¹⁷

The Few People Cured of HIV

HIV is not a curable disease in any general sense. Antiretroviral therapy controls the virus brilliantly, turning what was a death sentence into a manageable chronic condition. But the virus hides in long-lived reservoir cells that current drugs cannot reach, so stopping treatment leads to viral rebound in almost everyone. The exceptions are a handful of people who received bone marrow transplants from donors carrying a rare genetic mutation called CCR5-delta-32, which makes cells resistant to HIV infection.

The first and most famous case, known as the Berlin Patient, received a stem cell transplant from a CCR5-delta-32 homozygous donor to treat acute myeloid leukemia. He remained free of detectable HIV for over 20 months after stopping antiretroviral drugs, and subsequent follow-up confirmed the virus never returned.¹⁸ Several additional cases have since been documented. A recent report described a 63-year-old man who achieved HIV remission five years after a transplant from a CCR5-delta-32 sibling donor, with no intact HIV DNA detected in blood or gut biopsies and a gradual decline in HIV antibodies suggesting the infection had been eliminated.¹⁹

These cases are genuine cures, but they are not a treatment model. Bone marrow transplants are dangerous, expensive, and only justified when the patient also has a life-threatening blood cancer. The CCR5-delta-32 mutation is rare, found almost exclusively in people of Northern European descent. For the roughly 39 million people living with HIV worldwide, antiretroviral therapy remains the answer. Still, these cases proved something that researchers once debated: a true cure is biologically possible. That knowledge now drives research into gene therapies and other approaches that might replicate the outcome without requiring a transplant.²⁰

CAR T Cells in Leukemia and Autoimmune Disease

Chimeric antigen receptor T cell therapy, usually shortened to CAR T, re-engineers a patient’s own immune cells to hunt specific targets. The technology first proved itself in blood cancers. For children and young adults with B-cell acute lymphoblastic leukemia who had relapsed after every other treatment, CAR T cells targeting the CD19 protein on cancer cells could induce durable remissions and prolong survival when nothing else was working.²¹ The approach has since become an established alternative treatment for relapsed CD19-positive leukemias and lymphomas.²²

What surprised researchers was that the same approach could reset autoimmune diseases. In systemic lupus erythematosus, the immune system attacks the body’s own tissues, causing damage to the kidneys, brain, skin, and other organs. Standard treatment relies on long-term immunosuppressive drugs, which carry their own serious risks. Early trials using CD19-targeted CAR T cells in lupus patients have produced striking results. In a case series reported in the New England Journal of Medicine, all lupus patients achieved disease remission, and immunosuppressive therapy was completely stopped in every one of them.²³ A larger pooled analysis of 47 lupus patients across ten studies found that the vast majority met standard remission criteria, and most maintained drug-free remission at their last follow-up.²⁴

Whether CAR T for autoimmune diseases will prove to be a lasting cure or a very long remission is not yet clear. Follow-up periods so far range from about a month to nearly four years. But the possibility that a single treatment course could permanently reset a malfunctioning immune system, eliminating the need for lifelong drugs, has generated serious excitement in rheumatology. Early results in other autoimmune conditions like inflammatory myopathy and systemic sclerosis are also encouraging.

Cryptococcal Meningitis and the Access Problem

Not every curable deadly disease is a success story. Cryptococcal meningitis, a fungal infection of the brain, kills an estimated 180,000 people per year, mostly people with advanced HIV in sub-Saharan Africa. Effective treatment exists: a combination of amphotericin B and flucytosine significantly improves survival compared to alternatives. In a large randomized trial conducted across five African countries, one week of amphotericin B plus flucytosine was associated with the lowest ten-week mortality at about 24%.²⁵

The problem is that amphotericin B requires intravenous infusion and careful monitoring of kidney function, and flucytosine has been unavailable in most low-income countries for years.²⁶ Patients who cannot access the best regimen are treated with fluconazole alone, which is far less effective. The result is a disease where the cure is well established, clearly effective, and simply not available to the people who need it most. This pattern repeats across global health. The distance between a drug being approved somewhere and a patient swallowing it at the point of need can be enormous.

When the Cure Is Too Expensive to Scale

Gene and cell therapies have introduced a new version of this access gap. Zolgensma for SMA costs over two million dollars per dose, making it one of the most expensive drugs ever approved. CAR T cell therapy for cancer typically runs into the hundreds of thousands of dollars per patient. The manufacturing process is bespoke: a patient’s own cells are collected, genetically modified in a specialized facility, and shipped back. This does not lend itself to mass production, and the infrastructure required, from stem cell processing laboratories to trained specialists, simply does not exist in most of the world.²⁷

Hepatitis C illustrates how this tension can evolve. When the first direct-acting antivirals launched, a twelve-week course cost tens of thousands of dollars in the United States. Within a few years, generic manufacturers in countries like India and Egypt brought the price down dramatically, making mass treatment feasible. The biology of pill manufacturing helped: once you have the molecule, scaling production is straightforward compared to growing personalized cell products. Whether gene therapies will follow a similar cost trajectory is one of the central questions in medicine right now. The science of curing deadly diseases has raced ahead. The economics and logistics of delivering those cures remain, in many cases, a generation behind.